Status and phase
Conditions
Treatments
About
The primary purpose of the study is to evaluate the safety, reactogenicity, and immunogenicity of RBI-4000 administered at various dose levels via intramuscular injection and to determine the lowest dose of RBI-4000 necessary to elicit the rabies virus neutralizing antibody titer of equal or greater than (>=) 0.5 international unit per milliliter (IU/mL).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Any gender participants between 18 and 45 years old, inclusive, at the time of the first vaccination.
Body Mass Index >18 kilogram per square meter (Kg/m^2) and less than (<) 32 Kg/m^2.
Hematological/biochemical values within these parameters:
Female participants of non-childbearing potential or male participants with partners of childbearing potential may be enrolled in the study.
Female participants of childbearing potential may be enrolled in the study, if the participant
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
89 participants in 5 patient groups
Loading...
Central trial contact
Zelanna Goldberg Chief Medical Officer; Jessica Fowler
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal